206 related articles for article (PubMed ID: 34876170)
1. GTSE1 is possibly involved in the DNA damage repair and cisplatin resistance in osteosarcoma.
Xie C; Xiang W; Shen H; Shen J
J Orthop Surg Res; 2021 Dec; 16(1):713. PubMed ID: 34876170
[TBL] [Abstract][Full Text] [Related]
2. MicroRNA‑22 regulates autophagy and apoptosis in cisplatin resistance of osteosarcoma.
Meng CY; Zhao ZQ; Bai R; Zhao W; Wang YX; Sun L; Sun C; Feng W; Guo SB
Mol Med Rep; 2020 Nov; 22(5):3911-3921. PubMed ID: 33000186
[TBL] [Abstract][Full Text] [Related]
3. Suppressing CHD1L reduces the proliferation and chemoresistance in osteosarcoma.
Fan GT; Ling ZH; He ZW; Wu SJ; Zhou GX
Biochem Biophys Res Commun; 2021 May; 554():214-221. PubMed ID: 33813077
[TBL] [Abstract][Full Text] [Related]
4. Notch pathway inhibition using DAPT, a γ-secretase inhibitor (GSI), enhances the antitumor effect of cisplatin in resistant osteosarcoma.
Dai G; Deng S; Guo W; Yu L; Yang J; Zhou S; Gao T
Mol Carcinog; 2019 Jan; 58(1):3-18. PubMed ID: 29964327
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA‑22 mediates the cisplatin resistance of osteosarcoma cells by inhibiting autophagy via the PI3K/Akt/mTOR pathway.
Meng CY; Zhao ZQ; Bai R; Zhao W; Wang YX; Xue HQ; Sun L; Sun C; Feng W; Guo SB
Oncol Rep; 2020 Apr; 43(4):1169-1186. PubMed ID: 32323781
[TBL] [Abstract][Full Text] [Related]
6. ANXA2 and Rac1 negatively regulates autophagy and osteogenic differentiation in osteosarcoma cells to confer CDDP resistance.
Pan B; Pan Y; Wang S; Bai Y; Hu X; Yang Y; Wu L; Liu J
Biochem Biophys Res Commun; 2023 Oct; 676():198-206. PubMed ID: 37536195
[TBL] [Abstract][Full Text] [Related]
7. MicroRNAs as the pivotal regulators of cisplatin resistance in osteosarcoma.
Moghbeli M
Pathol Res Pract; 2023 Sep; 249():154743. PubMed ID: 37549518
[TBL] [Abstract][Full Text] [Related]
8. GTSE1 expression represses apoptotic signaling and confers cisplatin resistance in gastric cancer cells.
Subhash VV; Tan SH; Tan WL; Yeo MS; Xie C; Wong FY; Kiat ZY; Lim R; Yong WP
BMC Cancer; 2015 Jul; 15():550. PubMed ID: 26209226
[TBL] [Abstract][Full Text] [Related]
9. Long Non-coding RNAs in Cisplatin Resistance in Osteosarcoma.
Ferretti VA; León IE
Curr Treat Options Oncol; 2021 Mar; 22(5):41. PubMed ID: 33745006
[TBL] [Abstract][Full Text] [Related]
10. miR-223/Hsp70/JNK/JUN/miR-223 feedback loop modulates the chemoresistance of osteosarcoma to cisplatin.
Tang Q; Yuan Q; Li H; Wang W; Xie G; Zhu K; Li D
Biochem Biophys Res Commun; 2018 Mar; 497(3):827-834. PubMed ID: 29432736
[TBL] [Abstract][Full Text] [Related]
11. PPARγ Agonist Pioglitazone in Combination With Cisplatinum Arrests a Chemotherapy-resistant Osteosarcoma PDOX Model.
Higuchi T; Yamamoto J; Sugisawa N; Tashiro Y; Nishino H; Yamamoto N; Hayashi K; Kimura H; Miwa S; Igarashi K; Bouvet M; Singh SR; Tsuchiya H; Hoffman RM
Cancer Genomics Proteomics; 2020; 17(1):35-40. PubMed ID: 31882549
[TBL] [Abstract][Full Text] [Related]
12. The miR-34a-5p promotes the multi-chemoresistance of osteosarcoma via repression of the AGTR1 gene.
Pu Y; Zhao F; Li Y; Cui M; Wang H; Meng X; Cai S
BMC Cancer; 2017 Jan; 17(1):45. PubMed ID: 28073349
[TBL] [Abstract][Full Text] [Related]
13. P-Glycoprotein Overexpression Is Associated With Cisplatin Resistance in Human Osteosarcoma.
He C; Sun Z; Hoffman RM; Yang Z; Jiang Y; Wang L; Hao Y
Anticancer Res; 2019 Apr; 39(4):1711-1718. PubMed ID: 30952710
[TBL] [Abstract][Full Text] [Related]
14. Positive feedback loop SP1/MIR17HG/miR-130a-3p promotes osteosarcoma proliferation and cisplatin resistance.
Meng Y; Hao D; Huang Y; Jia S; Zhang J; He X; Sun L; Liu D
Biochem Biophys Res Commun; 2020 Jan; 521(3):739-745. PubMed ID: 31706574
[TBL] [Abstract][Full Text] [Related]
15. PLK2 modulation of enriched TAp73 affects osteogenic differentiation and prognosis in human osteosarcoma.
Li W; Zhang X; Xi X; Li Y; Quan H; Liu S; Wu L; Wu P; Lan W; Shao Y; Li H; Chen K; Hu Z
Cancer Med; 2020 Jun; 9(12):4371-4385. PubMed ID: 32349184
[TBL] [Abstract][Full Text] [Related]
16. miR-33a is up-regulated in chemoresistant osteosarcoma and promotes osteosarcoma cell resistance to cisplatin by down-regulating TWIST.
Zhou Y; Huang Z; Wu S; Zang X; Liu M; Shi J
J Exp Clin Cancer Res; 2014 Jan; 33(1):12. PubMed ID: 24468065
[TBL] [Abstract][Full Text] [Related]
17. LncRNA FOXD2-AS1 knockdown inhibits the resistance of human osteosarcoma cells to cisplatin by inhibiting miR-143 expression.
Zhang QQ; Xu SL; Ding C; Ma CC; Yuan TS; Hua CC; Wang XH
Eur Rev Med Pharmacol Sci; 2021 Jan; 25(2):678-686. PubMed ID: 33577022
[TBL] [Abstract][Full Text] [Related]
18. Enhancement effect of adenovirus-mediated antisense c-myc and caffeine on the cytotoxicity of cisplatin in osteosarcoma cell lines.
Xie XK; Yang DS; Ye ZM; Tao HM
Chemotherapy; 2009; 55(6):433-40. PubMed ID: 19996588
[TBL] [Abstract][Full Text] [Related]
19. Platinum agents in the treatment of osteosarcoma: efficacy of cisplatin vs. carboplatin in human osteosarcoma cell lines.
Robson H; Meyer S; Shalet SM; Anderson E; Roberts S; Eden OB
Med Pediatr Oncol; 2002 Dec; 39(6):573-80. PubMed ID: 12376980
[TBL] [Abstract][Full Text] [Related]
20. Downregulated Long Non-Coding RNA MSC-AS1 Inhibits Osteosarcoma Progression and Increases Sensitivity to Cisplatin by Binding to MicroRNA-142.
Zhang L; Zhao G; Ji S; Yuan Q; Zhou H
Med Sci Monit; 2020 Mar; 26():e921594. PubMed ID: 32155139
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
